GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
Source review / handoff

Asciminib (Scemblix), oral tablet

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

Check source scope before reading a dose

Scemblix - labeled renal guidance

Product / population
Asciminib (Scemblix), oral tablet
Renal method
Indexed GFR/eGFR, mL/min/1.73 m2
Source revision
DailyMed SPL version 13, posted Sep 29, 2026
Retrieved
2026-11-07
Local review status
Selected renal passages reviewed; independent clinician adjudication pending.

Documented differences and cautions on this drug

All record notes are retained here, including notes about sources not selected in this review.

Scemblix - product and source limitations

Dialysis lies outside the cited recommendation. Select the underlying regimen by indication.

What to reconcile: Apply only to the stated formulation, indication and renal population.

Selected renal passages reviewed; independent clinician adjudication pending.

Open this note and its source references
Official

Scemblix - labeled renal guidance

Open original reference

DailyMed / product prescribing information · Asciminib (Scemblix), oral tablet

Renal method: Indexed GFR/eGFR, mL/min/1.73 m2
Source date: DailyMed SPL version 13, posted Sep 29, 2026
Retrieved: 2026-11-07

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: 8.6 Renal Impairment

Asciminib requires no renal reduction at eGFR 15-89 mL/min/1.73 m2 in patients who do not require dialysis. Dialysis lies outside the cited recommendation. Select the underlying regimen by indication.

RDM74-scemblix-official-1 · Source locator: Renal guidance: 8.6 Renal Impairment

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e33001e7-3650-42b1-ae56-cddb5c43aa2b
Retrieved
2026-11-07
Renal-function method
Indexed GFR/eGFR, mL/min/1.73 m2
Source date/version
DailyMed SPL version 13, posted Sep 29, 2026
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
0d29cbc11d5a442feb9118e4248ff55a545323b2d1f253ca1ae8e9f983e7f215

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=rx-scemblix&s1=RDM74-scemblix-official&h1=42076898f6da8c1bdbf680c53a865c13cf5187ddee458aff3da04117117535a9

Top